|Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large …|
DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ...
Journal of clinical oncology 27 (34), 5794-5799, 2009
|Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group|
M Dowsett, TO Nielsen, R A’Hern, J Bartlett, RC Coombes, J Cuzick, ...
Journal of the National cancer Institute 103 (22), 1656-1664, 2011
|Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk|
HK Meier-Ewert, PM Ridker, N Rifai, MM Regan, NJ Price, DF Dinges, ...
Journal of the American College of Cardiology 43 (4), 678-683, 2004
|Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial|
V Galimberti, BF Cole, S Zurrida, G Viale, A Luini, P Veronesi, P Baratella, ...
The lancet oncology 14 (4), 297-305, 2013
|Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma|
DF McDermott, MM Regan, JI Clark, LE Flaherty, GR Weiss, TF Logan, ...
Journal of clinical oncology 23 (1), 133-141, 2004
|Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer|
Q Wang, W Li, Y Zhang, X Yuan, K Xu, J Yu, Z Chen, R Beroukhim, ...
Cell 138 (2), 245-256, 2009
|The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer|
MM Pomerantz, N Ahmadiyeh, L Jia, P Herman, MP Verzi, ...
Nature genetics 41 (8), 882-884, 2009
|Adjuvant exemestane with ovarian suppression in premenopausal breast cancer|
O Pagani, MM Regan, BA Walley, GF Fleming, M Colleoni, I Láng, ...
New England Journal of Medicine 371 (2), 107-118, 2014
|De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017|
G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ...
Annals of Oncology 28 (8), 1700-1712, 2017
|External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study|
DYC Heng, W Xie, MM Regan, LC Harshman, GA Bjarnason, ...
The lancet oncology 14 (2), 141-148, 2013
|Adjuvant ovarian suppression in premenopausal breast cancer|
PA Francis, MM Regan, GF Fleming, I Láng, E Ciruelos, M Bellet, ...
New England Journal of Medicine 372 (5), 436-446, 2015
|Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer|
M Atkins, M Regan, D McDermott, J Mier, E Stanbridge, A Youmans, ...
Clinical cancer research 11 (10), 3714-3721, 2005
|Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy …|
G Viale, MM Regan, E Maiorano, MG Mastropasqua, P Dell'Orto, ...
Journal of Clinical Oncology 25 (25), 3846-3852, 2007
|Association of cystic fibrosis with abnormalities in fatty acid metabolism|
SD Freedman, PG Blanco, MM Zaman, JC Shea, M Ollero, IK Hopper, ...
New England Journal of Medicine 350 (6), 560-569, 2004
|Melatonin treatment for age-related insomnia|
IV Zhdanova, RJ Wurtman, MM Regan, JA Taylor, JP Shi, OU Leclair
The Journal of Clinical Endocrinology & Metabolism 86 (10), 4727-4730, 2001
|Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical …|
MM Regan, P Neven, A Giobbie-Hurder, A Goldhirsch, B Ejlertsen, ...
The lancet oncology 12 (12), 1101-1108, 2011
|8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC|
N Ahmadiyeh, MM Pomerantz, C Grisanzio, P Herman, L Jia, V Almendro, ...
Proceedings of the National academy of sciences 107 (21), 9742-9746, 2010
|Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International …|
G Viale, A Giobbie-Hurder, MM Regan, AS Coates, MG Mastropasqua, ...
Journal of clinical oncology 26 (34), 5569, 2008
|CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial|
MM Regan, B Leyland-Jones, M Bouzyk, O Pagani, W Tang, R Kammler, ...
Journal of the National Cancer Institute 104 (6), 441-451, 2012
|Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials|
B Asselain, W Barlow, J Bartlett, J Bergh, E Bergsten-Nordström, J Bliss, ...
The Lancet Oncology 19 (1), 27-39, 2018